These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23144447)

  • 1. Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis.
    Das S; Fernandez Matilla M; Dass S; Buch MH; Rawstron AC; Vital EM; Emery P
    Ann Rheum Dis; 2013 Mar; 72(3):463-4. PubMed ID: 23144447
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis.
    Lehane PB; Lacey S; Hessey EW; Jahreis A
    Ann Rheum Dis; 2014 Oct; 73(10):1906-8. PubMed ID: 25074690
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    Arts EE; Jansen TL; Den Broeder A; Vonkeman HE; Dutmer E; Van de Laar MA; Van Riel PL; Fransen J
    Ann Rheum Dis; 2011 May; 70(5):877-8. PubMed ID: 20956405
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients.
    Mazilu D; Gudu T; Ionescu R; Opris D
    Biomed Res Int; 2014; 2014():689426. PubMed ID: 24511542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B lymphocyte-typing for prediction of clinical response to rituximab.
    Brezinschek HP; Rainer F; Brickmann K; Graninger WB
    Arthritis Res Ther; 2012 Jul; 14(4):R161. PubMed ID: 22770118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab treatment in rheumatoid arthritis: how does it work?
    Boumans MJ; Tak PP
    Arthritis Res Ther; 2009; 11(6):134. PubMed ID: 20017888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
    Vital EM; Dass S; Rawstron AC; Buch MH; Goëb V; Henshaw K; Ponchel F; Emery P
    Arthritis Rheum; 2010 May; 62(5):1273-9. PubMed ID: 20131284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell therapies in established rheumatoid arthritis.
    Leandro MJ; Becerra-Fernandez E
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
    Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
    Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell therapies for rheumatoid arthritis.
    Scher JU
    Bull NYU Hosp Jt Dis; 2012; 70(3):200-3. PubMed ID: 23259629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis.
    Bruzzese V
    Int J Immunopathol Pharmacol; 2011; 24(1):265-7. PubMed ID: 21496414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.
    Vital EM; Rawstron AC; Dass S; Henshaw K; Madden J; Emery P; McGonagle D
    Arthritis Rheum; 2011 Mar; 63(3):603-8. PubMed ID: 21360489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
    Dass S; Vital EM; Emery P
    Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
    Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
    Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
    Shaw T; Quan J; Totoritis MC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
    [No Abstract]   [Full Text] [Related]  

  • 17. The updated guidelines on the use of rituximab in rheumatoid arthritis.
    Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
    Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
    [No Abstract]   [Full Text] [Related]  

  • 18. More or less rituximab? Biology and clinic, regulators and researchers.
    van Vollenhoven RF
    Arthritis Rheum; 2011 Mar; 63(3):594-6. PubMed ID: 21360487
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis.
    Narváez J; Hernández MV; Ruiz JM; Vaquero CG; Juanola X; Nollaa JM
    Joint Bone Spine; 2011 Jan; 78(1):101-3. PubMed ID: 21067952
    [No Abstract]   [Full Text] [Related]  

  • 20. Rheumatoid arthritis: When should we use rituximab to treat RA?
    Yazici Y
    Nat Rev Rheumatol; 2011 May; 7(7):379-80. PubMed ID: 21629243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.